United States

People: Jounce Therapeutics Inc (JNCE.OQ)

JNCE.OQ on NASDAQ Stock Exchange Global Select Market

21 Mar 2018
Change (% chg)

$-0.79 (-3.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Higgons, J. Duncan 

Mr. J. Duncan Higgons is an Independent Director of the Company. He has served as a director on our board of directors since November 2015. Mr. Higgons recently served as chief operating officer of Agios Therapeutics, Inc., or Agios, from 2009 to 2016. Prior to joining Agios, Mr. Higgons served as executive vice-president, and interim president and chief executive officer at Archemix Corporation, or Archemix, from 2006 to 2009. Prior to Archemix, Mr. Higgons served as the chief commercial officer at TransForm Pharmaceuticals, Inc., a privately-held biotechnology company, which was acquired by Johnson & Johnson Company. Mr. Higgons holds a B.Sc. in Mathematics from King's College University of London and a M.Sc. in Economics from London Business School.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --